Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott To Assert New Biaxin XL Patent In Ongoing Suits

This article was originally published in The Pink Sheet Daily

Executive Summary

Abbott is asserting its new pharmacokinetic patent issued for Biaxin XL (clarithromycin extended-release) in ongoing litigation, the company said during its earnings call April 12

You may also be interested in...



Teva’s Biaxin XL Generic Barred From Launch Pending May 26 Hearing

A temporary restraining order prevents Teva from launching its extended-release generic upon the May 23 expiration of the clarithromycin compound patent. Abbott already has gotten a jump on potential generic versions of immediate-release Biaxin with an “authorized” generic sold through Dava.

Teva’s Biaxin XL Generic Barred From Launch Pending May 26 Hearing

A temporary restraining order prevents Teva from launching its extended-release generic upon the May 23 expiration of the clarithromycin compound patent. Abbott already has gotten a jump on potential generic versions of immediate-release Biaxin with an “authorized” generic sold through Dava.

Abbott To Bolster Biaxin XL Patent Protection Ahead Of Compound Expiration In May

The additional intellectual property for the extended-release formulation will give generic firms “something to think about,” Abbott CFO Freyman says at SG Cowen investor conference. Abbott says it filed suit against three generic manufacturers March 14.

Related Content

Topics

UsernamePublicRestriction

Register

PS061961

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel